以下文章来源于清科研究 ，作者创造价值的 清科研究 . 清科研究中心致力于为众多的有限合伙人、VC/PE机构、战略投资者、以及政府机构、律师事务所、会计事务所、投资银行、研究机构等提供专业的信 息、数据、研究和咨询服务。 回暖复苏。 作者 / 清科研究 来源 / 清科研究 （ID：pedata2017） 2 0 2 5年中国股权投资市场募投退全方位回暖。 募资方面，2 0 2 5年新募集基金 数量和规模分别为5 , 0 3 9只，1 . 6 5万亿元，同比分别上升2 6 . 6 %、1 4 . 1 % ，政府投资基金、地方国资 平台、险资、AIC等出资人活跃出资，成为推动募资市场回暖的核心力量。币种结构上，人民币基金主导地位进一步提升，募资规模 同比上升1 6 . 1 %；外币基金募资延续下滑态势，全年仅3 3只外币基金完成新一轮募集，募集规模超3 5 0亿元，同比分别下滑1 5 . 4 %、 3 6 . 0 %。 投资方面，2 0 2 5年投资案例数和金额分别为1 0 , 7 9 5起、9 , 2 8 7 . 1 6亿元，同比上升2 8 . 4 %、4 5 . 6 %。分行业看，硬科技仍是投资主流 领 域 ...

Group 1 - The A-share market opened lower and experienced significant adjustments, while the healthcare sector showed resilience with major stocks like WuXi AppTec rising over 1% and Aier Eye Hospital increasing by over 2% [1] - The largest healthcare ETF (512170) has seen a net subscription of 2.688 billion yuan over the past 13 days, indicating strong investor interest [1] - The pharmaceutical sector showed mixed performance, with innovative drug concepts mostly declining, while traditional Chinese medicine stocks like Darentang rose over 4% [3] Group 2 - The National Medical Products Administration announced support for the biomanufacturing industry during the 14th Five-Year Plan, aiming to shift the pharmaceutical industry towards systematic innovation and quality growth [5] - Analysts are optimistic about the Chinese medicine sector's recovery driven by policy support, cost improvements, and expected adjustments in the essential drug catalog [5] - Zhongtai Securities is bullish on the raw material drug sector, anticipating price improvements after several years of price declines, with most API product prices at historical lows [5] Group 3 - The largest healthcare ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [5] - The only pharmaceutical ETF (562050) has over 60% allocation in innovative drugs while also considering high-dividend Chinese medicine stocks [5] - As of February 3, 2026, the healthcare ETF has a total scale of 27.5 billion yuan, making it the largest in the market [6]

Core Viewpoint - The innovative drug ETF Tianhong (517380) has shown strong performance, with significant inflows and positive market reactions to earnings reports from key companies in the sector, particularly Eli Lilly's impressive revenue growth driven by weight loss drugs [2][3]. Group 1: ETF Performance - As of February 5, 2026, the innovative drug ETF Tianhong (517380) recorded a transaction volume of 4.9451 million yuan, with the tracked index HSSSHID rising by 0.11% [1]. - Over the past 20 trading days, the innovative drug ETF Tianhong (517380) attracted a total of 395 million yuan [2]. Group 2: Company Highlights - Eli Lilly reported a 43% year-over-year increase in Q4 revenue, reaching 19.29 billion dollars, with adjusted earnings per share of 7.54 dollars, both exceeding market expectations [2]. - Eli Lilly's weight loss drugs, Mounjaro and Zepbound, generated over 11.6 billion dollars in sales, accounting for more than 60% of total revenue [2]. - The company projects full-year revenue for 2026 to be between 80 billion and 83 billion dollars, with adjusted earnings per share expected to be between 33.50 and 35 dollars, also surpassing market forecasts [2]. Group 3: Industry Insights - Donghai Securities anticipates that the innovative drug sector will enter a phase of accelerated profit realization by 2025, with companies like Nocare and Rongchang Biopharma turning profitable [3]. - The core drivers of this growth are rapid commercialization of products and business development (BD) collaborations, with companies leveraging both to enhance profitability [3]. - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product commercialization supported by healthcare insurance being a fundamental growth driver [3].

信达生物2月4日公布其2025全年业绩，总产品收入约人民币119亿元，同比保持约45%的强劲增长态 势。2025年Q4，信达生物有6款新药纳入2026年国家医保目录。 东海证券表示，2025年创新药板块进入盈利兑现提速期，诺诚健华、荣昌生物等实现扭亏为盈，三生国 健等业绩大幅预增，君实生物等显著减亏，核心驱动主要来自商业化产品快速放量和BD合作两大主 线。 2月5日早盘，港股市场主要指数集体下挫，聚焦创新药、AI医疗主线的港股通医疗ETF(520510)一度逆 势翻红，脑动极光、药明康德（603259）、凯莱英（002821）等持仓股涨幅靠前。 ...

Group 1 - The pharmaceutical industry is experiencing continuous catalytic developments, with significant capital inflow into the Science and Technology Innovation Drug ETF (Guotai, 589720), which has seen nearly 1 billion yuan in net inflows over the past 20 days, indicating active capital positioning [1] - According to Zhongtai Securities, the raw material drug/intermediate industry has undergone 4-5 years of price decline, and with the rise in commodity and upstream chemical prices, a price improvement is expected. Most API product prices are at historical low levels, with limited profit margins and a low probability of further decline, showing a significant stabilization trend [1] - Innovative drug sectors such as small nucleic acids, peptides, and ADC toxins are continuously catalyzing the industry chain, contributing new business increments for raw material drug companies [1] Group 2 - The Science and Technology Innovation Drug ETF (Guotai, 589720) tracks the Science and Technology Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%. This index focuses on new drug research and development driven by technological innovation, covering companies in the biopharmaceutical and chemical pharmaceutical sectors with high R&D investment and innovation capabilities, reflecting the overall trend of innovation development in China's pharmaceutical industry, with a focus on growth style in its allocation [1]

Fundraising - In 2025, the number and scale of newly raised funds in China's equity investment market reached 5,039 and 1.65 trillion yuan, representing year-on-year increases of 26.6% and 14.1% respectively [1] - Government investment funds, local state-owned platforms, insurance capital, and AIC have become the core driving forces behind the recovery of the fundraising market [1] - The dominance of RMB funds has further increased, with a year-on-year growth of 16.1%, while foreign currency funds continued to decline, with only 33 foreign currency funds completing new rounds of fundraising, totaling over 35 billion yuan, down 15.4% and 36.0% year-on-year [1] Investment - In 2025, the number and amount of investment cases reached 10,795 and 928.716 billion yuan, showing year-on-year increases of 28.4% and 45.6% respectively [1] - Hard technology remains the mainstream investment sector, with investment case numbers in IT, semiconductors, biotechnology/healthcare, and machinery manufacturing all exceeding 1,500 [1] - High interest is noted in sub-sectors such as AI, embodied intelligence, GPU, innovative drugs, smart manufacturing, and new energy/new materials [1] - The popularity of investment strategies such as mergers and acquisitions, cornerstone investments, and public offerings has also significantly increased [1] Exits - The number of exit cases in 2025 saw a significant increase, totaling 5,211, which is a year-on-year rise of 41.0% [2] - Nearly 2,000 IPO cases were recorded, marking a year-on-year increase of 46.8% [2] - The number of merger and acquisition exit cases reached 468, reflecting a year-on-year increase of 77.3% [2]

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is focusing on enhancing its strategic partnerships and technological advancements in the healthcare sector, particularly through AI applications and e-commerce platforms [2][3]. Group 1: Company Developments - On October 23, 2025, the company established a strategic partnership with iFlytek Medical to enhance professional service efficiency in pharmacies and address user health needs through the launch of the "Pharmacy AI Health Assistant" [2]. - As of September 30, 2023, the company reported a revenue of 3.892 billion yuan, representing a year-on-year growth of 19.06%, and a net profit of 157 million yuan, with a significant increase of 45.21% compared to the previous year [8]. - The company has a diverse business model, with 97.60% of its revenue coming from traditional Chinese and Western medicines, and 2.40% from other supplementary sources [7]. Group 2: Market Position and Shareholder Information - As of September 30, 2023, the company had 20,100 shareholders, a decrease of 22.86% from the previous period, while the average number of shares held per shareholder increased by 29.64% to 7,422 shares [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company's shares, and the company collaborates with various Alibaba platforms, including Alipay and Tmall [3]. - The company’s stock has shown a net inflow of 4.3028 million yuan today, with a total market capitalization of 8.684 billion yuan [1].

Core Viewpoint - WuXi AppTec is experiencing growth due to its position as a leading Contract Research Organization (CRO) and its benefits from the depreciation of the Renminbi, with a significant portion of its revenue coming from overseas markets [2][3]. Company Overview - WuXi AppTec is an international leader in providing integrated new drug research and production services for the global biopharmaceutical industry, focusing on small molecule chemical drug discovery, development, and production [2]. - The company has a comprehensive platform service model that caters to global pharmaceutical companies, including medical device testing and precision medical research and production services abroad [2]. - As of September 30, 2025, WuXi AppTec reported a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit of 12.076 billion yuan, with an impressive growth of 84.84% [7]. Financial Performance - The company’s overseas revenue accounted for 78.67% of its total revenue, benefiting from the depreciation of the Renminbi [3]. - The main business revenue composition includes chemical business (78.37%), testing business (12.93%), biological business (6.02%), and other services [7]. - WuXi AppTec has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [8]. Market Activity - On February 4, the stock price of WuXi AppTec increased by 1.07%, with a trading volume of 3.14 billion yuan and a turnover rate of 1.34%, leading to a total market capitalization of 285.277 billion yuan [1]. - The stock has seen a net inflow of 118 million yuan from major investors, indicating a positive sentiment in the market [4][5].

来源：新浪证券-红岸工作室 2月4日，海普瑞涨1.33%，成交额5135.06万元，换手率0.34%，总市值179.01亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1918.43万，占总成交额的6.25%。 技术面：筹码平均交易成本为11.66元 该股筹码平均交易成本为11.66元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近压力位 12.37，谨防压力位处回调，若突破压力位则可能会 ...

Group 1 - The article discusses the performance and characteristics of various ETFs tracking the STAR Market indices, highlighting their focus on high-tech sectors such as semiconductors, medical devices, and software development [2][3] - The STAR 50 ETF tracks the STAR 50 Index, which consists of 50 stocks with large market capitalization and good liquidity, with over 65% of its composition in semiconductors and nearly 80% in hard technology sectors [2] - The STAR 100 ETF focuses on 100 medium-cap stocks, with over 75% of its composition in electronics, power equipment, and pharmaceutical industries [2] - The STAR 200 ETF targets 200 small-cap stocks, emphasizing growth potential, with significant representation from electronics, biomedical, and machinery sectors [2] - The STAR Composite Index ETF covers all market segments and focuses on core industries such as artificial intelligence, semiconductors, and innovative pharmaceuticals, encompassing all 17 primary industries listed on the STAR Market [3] - The STAR Growth ETF includes 50 stocks with high growth rates in revenue and net profit, with over 65% of its composition in the electronics and communications sectors [3] Group 2 - As of the midday close on February 4, 2026, the STAR 50 Index showed a decline, while the STAR 100 Index had a rolling P/E ratio of 213.8 times, and the STAR 200 Index had a rolling P/E ratio of 167.4 times [2] - The STAR Composite Index had a rolling P/E ratio of 223.3 times, and the STAR Growth Index had a rolling P/E ratio of 193.2 times, indicating varying levels of valuation across these indices [3] - The article notes that the STAR Market indices have been established at different times, with the STAR 50 Index launched on July 23, 2020, the STAR 100 Index on August 7, 2023, the STAR 200 Index on August 20, 2024, and the STAR Composite Index on November 4, 2022 [3]